Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.

The effect of local and systemic injections of mesenchymal stem cells derived from adipose tissue (AD-MSC) into rabbit models of corneal allograft rejection with either normal-risk or high-risk vascularized corneal beds was investigated. The models we present in this study are more similar to human...

Full description

Saved in:
Bibliographic Details
Main Authors: Sherezade Fuentes-Julián, Francisco Arnalich-Montiel, Laia Jaumandreu, Marina Leal, Alfonso Casado, Ignacio García-Tuñon, Enrique Hernández-Jiménez, Eduardo López-Collazo, Maria P De Miguel
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0117945&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850023217660428288
author Sherezade Fuentes-Julián
Francisco Arnalich-Montiel
Laia Jaumandreu
Marina Leal
Alfonso Casado
Ignacio García-Tuñon
Enrique Hernández-Jiménez
Eduardo López-Collazo
Maria P De Miguel
author_facet Sherezade Fuentes-Julián
Francisco Arnalich-Montiel
Laia Jaumandreu
Marina Leal
Alfonso Casado
Ignacio García-Tuñon
Enrique Hernández-Jiménez
Eduardo López-Collazo
Maria P De Miguel
author_sort Sherezade Fuentes-Julián
collection DOAJ
description The effect of local and systemic injections of mesenchymal stem cells derived from adipose tissue (AD-MSC) into rabbit models of corneal allograft rejection with either normal-risk or high-risk vascularized corneal beds was investigated. The models we present in this study are more similar to human corneal transplants than previously reported murine models. Our aim was to prevent transplant rejection and increase the length of graft survival. In the normal-risk transplant model, in contrast to our expectations, the injection of AD-MSC into the graft junction during surgery resulted in the induction of increased signs of inflammation such as corneal edema with increased thickness, and a higher level of infiltration of leukocytes. This process led to a lower survival of the graft compared with the sham-treated corneal transplants. In the high-risk transplant model, in which immune ocular privilege was undermined by the induction of neovascularization prior to graft surgery, we found the use of systemic rabbit AD-MSCs prior to surgery, during surgery, and at various time points after surgery resulted in a shorter survival of the graft compared with the non-treated corneal grafts. Based on our results, local or systemic treatment with AD-MSCs to prevent corneal rejection in rabbit corneal models at normal or high risk of rejection does not increase survival but rather can increase inflammation and neovascularization and break the innate ocular immune privilege. This result can be partially explained by the immunomarkers, lack of immunosuppressive ability and immunophenotypical secretion molecules characterization of AD-MSC used in this study. Parameters including the risk of rejection, the inflammatory/vascularization environment, the cell source, the time of injection, the immunosuppression, the number of cells, and the mode of delivery must be established before translating the possible benefits of the use of MSCs in corneal transplants to clinical practice.
format Article
id doaj-art-57f03104c94942f1a4dcdbebf3f148f2
institution DOAJ
issn 1932-6203
language English
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-57f03104c94942f1a4dcdbebf3f148f22025-08-20T03:01:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e011794510.1371/journal.pone.0117945Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.Sherezade Fuentes-JuliánFrancisco Arnalich-MontielLaia JaumandreuMarina LealAlfonso CasadoIgnacio García-TuñonEnrique Hernández-JiménezEduardo López-CollazoMaria P De MiguelThe effect of local and systemic injections of mesenchymal stem cells derived from adipose tissue (AD-MSC) into rabbit models of corneal allograft rejection with either normal-risk or high-risk vascularized corneal beds was investigated. The models we present in this study are more similar to human corneal transplants than previously reported murine models. Our aim was to prevent transplant rejection and increase the length of graft survival. In the normal-risk transplant model, in contrast to our expectations, the injection of AD-MSC into the graft junction during surgery resulted in the induction of increased signs of inflammation such as corneal edema with increased thickness, and a higher level of infiltration of leukocytes. This process led to a lower survival of the graft compared with the sham-treated corneal transplants. In the high-risk transplant model, in which immune ocular privilege was undermined by the induction of neovascularization prior to graft surgery, we found the use of systemic rabbit AD-MSCs prior to surgery, during surgery, and at various time points after surgery resulted in a shorter survival of the graft compared with the non-treated corneal grafts. Based on our results, local or systemic treatment with AD-MSCs to prevent corneal rejection in rabbit corneal models at normal or high risk of rejection does not increase survival but rather can increase inflammation and neovascularization and break the innate ocular immune privilege. This result can be partially explained by the immunomarkers, lack of immunosuppressive ability and immunophenotypical secretion molecules characterization of AD-MSC used in this study. Parameters including the risk of rejection, the inflammatory/vascularization environment, the cell source, the time of injection, the immunosuppression, the number of cells, and the mode of delivery must be established before translating the possible benefits of the use of MSCs in corneal transplants to clinical practice.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0117945&type=printable
spellingShingle Sherezade Fuentes-Julián
Francisco Arnalich-Montiel
Laia Jaumandreu
Marina Leal
Alfonso Casado
Ignacio García-Tuñon
Enrique Hernández-Jiménez
Eduardo López-Collazo
Maria P De Miguel
Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.
PLoS ONE
title Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.
title_full Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.
title_fullStr Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.
title_full_unstemmed Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.
title_short Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.
title_sort adipose derived mesenchymal stem cell administration does not improve corneal graft survival outcome
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0117945&type=printable
work_keys_str_mv AT sherezadefuentesjulian adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome
AT franciscoarnalichmontiel adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome
AT laiajaumandreu adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome
AT marinaleal adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome
AT alfonsocasado adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome
AT ignaciogarciatunon adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome
AT enriquehernandezjimenez adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome
AT eduardolopezcollazo adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome
AT mariapdemiguel adiposederivedmesenchymalstemcelladministrationdoesnotimprovecornealgraftsurvivaloutcome